2:05
How Blood Cancer Cells Rewire to Evade Drug Treatment | Oncotarget
Oncotarget
1:56
Preclinical & Clinical Evaluation of Janus Kinase Inhibitor Ruxolitinib in MM | Oncotarget
1:05
Fate of Drug Discovery in Academia; Dumping in Publication Landfill? | Oncotarget
1:52
Therapeutic Potentials and Challenges of Cytostatic Persister Cancer Cells | Oncotarget
1:46
Inhibiting BRAF/EGFR/MEK for Colorectal Cancer | Oncotarget
1:17
Repurposing DPP4 Inhibitors for Target Therapy Resistance in Renal Cell Carcinoma | Oncotarget
1:43
Targeting the Src N-Terminal Regulatory Element in Cancer | Oncotarget
1:20
Cancer Prevention with Rapamycin | Oncotarget
2:31
A Phase I Trial of Riluzole and Sorafenib in Patients with Advanced Solid Tumors | Oncotarget
1:34
Selective Protection of Normal Cells from Chemotherapy, While Killing Drug-Resistant Cancer Cells
2:18
Everolimus Inhibits Angiogenesis, Lymphangiogenesis in TP53 Mutant HNSCC | Oncotarget
2:15
Healing Effects & Genotoxicity of Andiroba Oil vs LLLT for Oral Mucositis in Hamsters | Oncotarget
Oncolytic Myxoma Viruses Fight Multiple Myeloma | Oncotarget
0:51
Oncotarget: Potential Mechanisms of Resistance to EMT
5:24
The Netherlands Cancer Institute's Dr. Bernards & Diede Brunen talk with Oncotarget
6:25
University of Texas Medical School's Dr. Anutosh Ganguly talks about his Publication in Oncotarget
